期刊： BLOOD CANCER JOURNAL, 2022; 12 (3)
Janus kinase 2 (JAK2) hyperactivation by JAK2(V617F) mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promisi......
期刊： BLOOD CANCER JOURNAL, 2022; 12 (2)
Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these bio......
期刊： BLOOD CANCER JOURNAL, 2022; 12 (7)
To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor T (CAR-T) cells, we developed the FasT CAR-T (F-CAR-T) nex......
期刊： BLOOD CANCER JOURNAL, 2022; 12 (11)
The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has been demonstrated to have comparable effectiveness or better to ATRA ......
期刊： BLOOD CANCER JOURNAL, 2022; 12 (2)
Immunotherapy with CD19-targeting bispecific T-cell engagers (CD19BiTEs) has demonstrated highly effective killing of cancer cells in patients with pr......
期刊： BLOOD CANCER JOURNAL, 2022; 12 (6)
Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leu......
